These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

MORGANTOWN – WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for ...

While there are no studies documenting the number of physicians taking GLP-1s, a number of physicians told the Times that they've noticed many colleagues growing thinner and sharing similar eating ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...

designed to cater to the growing needs of individuals using GLP-1 medications like Ozempic and Wegovy. This new line of meals offers a perfect balance of nutrition and flavor, without compromise ...

The year-over-year increase in revenues was driven by higher Diabetes and Obesity Care sales as GLP-1 product sales increased ... Obesity Care (Saxenda and Wegovy) sales were up 91% to DKK 21.4 ...

but oral GLP-1 Rybelsus has had slower uptake, and Lilly's newly approved Mounjaro provides strong competition Novo's obesity drug Wegovy had a slow launch due to supply constraints, and Zepbound ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...

There’s been growing data showing that GLP-1 drugs can enter and exert effects ... is running two large trials of the obesity drug Wegovy in Alzheimer’s that are expected to report data ...